<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020123</url>
  </required_header>
  <id_info>
    <org_study_id>D1020C00009</org_study_id>
    <nct_id>NCT01020123</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients</brief_title>
  <official_title>A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, With an Optional 2-month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on
      Treatment to Metformin in TD2M Patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c: Change From Baseline to 4 Month</measure>
    <time_frame>Baseline to 4th Month</time_frame>
    <description>AZD1656 is analyzed in a ANCOVA model (Glipized and Open Label is Not Included in the model), FAS Prior to Rescue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FPG: to Evaluate Change From Baseline to 4 Month, Compared With Placebo, FAS Prior to Rescue.</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>AZD1656 is analyzed in a ANCOVA model (Glipized and Open Label is Not Included in the model), FAS Prior to Rescue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SMPG: Change From Baseline to 4 Month, Compared With Placebo, FAS Prior to Rescue.</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>AZD1656 is analyzed in a ANCOVA model (Glipized and Open Label is Not Included in the model), FAS Prior to Rescue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OGTT/Plasma Glucose</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>The relative change in AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OGTT/Insulin</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>The Relative Change in AUC FAS Prior to Rescue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OGTT/C-peptide</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>The relative change, FAS prior to rescue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OGTT/Pro-insulin/Insulin</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>The relative change, FAS prior to rescue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c ≤ 7</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Number of responders ≤ 7, FAS prior to rescue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c ≤ 6.5</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Number of Responders ≤ 6.5, FAS Prior to Rescue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C: Mean Ratio</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-C: Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol: Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides: Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein: Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure, Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure, Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse, Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight, Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcF; Electorcardiagram Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin; Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes; Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium; Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium; Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine; Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT; Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST; Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline Phosphatase; Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin; Change From Baseline</measure>
    <time_frame>baseline to 4 month</time_frame>
    <description>Summary statistic of change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F to Characterise the PK Properties of AZD1656.</measure>
    <time_frame>at 4 month</time_frame>
    <description>The value is calculated using an allometric model (of a patient weighting 75 kg). The value is independent treatment given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EC50 to Characterise the PD Properties of AZD1656.</measure>
    <time_frame>at 4 month</time_frame>
    <description>The value is model based. The value is independent treatment given.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">530</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1656</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1656</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1656</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1656</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1656</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glipizide administered to 1 group of patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1656</intervention_name>
    <description>Different doses of AZD1656 administered to 5 groups of patients</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>AZD1656 placebo and glipizide placebo administered to 1 group of patients</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glipizide</intervention_name>
    <description>Glipizide administered to 1 group of patients</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female of non-childbearing potential

          -  Treated with maximally tolerated dose of metformin (≥ 1500mg/day) for at least 10
             weeks prior to enrolment.

          -  Patients with HbA1c ≥ 7.5 but ≤ 10% at enrolment visit (Visit 1) can enter cohort
             1.Patients with HbA1c between &gt;10 % and &lt;12 % can enter the open-label arm with
             AZD1656 (cohort 2)

        Exclusion Criteria:

          -  Significant cardiovascular event within the last 6 months prior to enrolment or heart
             failure New York Heart Association (NYHA) class III-IV.

          -  Impaired renal function in terms of GFR&lt;60 ml/min, based on Modification of Diet in
             Renal Disease Study Group (MDRD) calculation.

          -  Use of warfarin or amiodarone within 3 months prior to enrolment (screening) and use
             of potent CYP450 inhibitors, eg, ketoconazole and/or macrolide antibiotics within 14
             days before randomisation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Johnsson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Mölndal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Wilding, DM FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Aintree</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Temuco</city>
        <state>Novena Region</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>TN</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <state>SN</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>TN</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Görlitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lubeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Laurent</city>
        <state>QC</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dunaujvaros</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szekszard</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szigetvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>TN</state>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jekabpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jelgava</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Limbazi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Talsi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>TN</state>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>TN</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meridas</city>
        <state>Yucatan</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>TN</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Callao</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lambayeque</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piura</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trujillo</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>TN</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kutno</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alba Iulia</city>
        <state>Alba</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tg Mures</city>
        <state>Mures</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>TN</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>TN</state>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paignton</city>
        <state>Devon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Laurent</city>
        <state>QC</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stevenage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Bromwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Lothian</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <results_first_submitted>July 24, 2012</results_first_submitted>
  <results_first_submitted_qc>November 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2012</results_first_posted>
  <last_update_submitted>November 22, 2012</last_update_submitted>
  <last_update_submitted_qc>November 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type II Diabetes Mellitus</keyword>
  <keyword>metformin</keyword>
  <keyword>glipizide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glipizide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Higher Dose</title>
          <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
        </group>
        <group group_id="P2">
          <title>Lower Dose</title>
          <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
        </group>
        <group group_id="P3">
          <title>40 mg Fixed Dose</title>
          <description>40 mg AZD1656 add on to metformin, fixed dose</description>
        </group>
        <group group_id="P4">
          <title>20 mg Fixed Dose</title>
          <description>20 mg AZD1656 add on to metformin, fixed dose</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo add on to metformin</description>
        </group>
        <group group_id="P6">
          <title>Glipizide</title>
          <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
        </group>
        <group group_id="P7">
          <title>Open Label</title>
          <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="88"/>
                <participants group_id="P6" count="94"/>
                <participants group_id="P7" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="77"/>
                <participants group_id="P6" count="83"/>
                <participants group_id="P7" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility Criteria not fullfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclasified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40">Not everyone accepted protocol amendment allowing to enter extension period or was asked to enter.</participants>
                <participants group_id="P2" count="35">Not everyone accepted protocol amendment allowing to enter extension period or was asked to enter.</participants>
                <participants group_id="P3" count="19">Not everyone accepted protocol amendment allowing to enter extension period or was asked to enter.</participants>
                <participants group_id="P4" count="13">Not everyone accepted protocol amendment allowing to enter extension period or was asked to enter.</participants>
                <participants group_id="P5" count="31">Not everyone accepted protocol amendment allowing to enter extension period or was asked to enter.</participants>
                <participants group_id="P6" count="38">Not everyone accepted protocol amendment allowing to enter extension period or was asked to enter.</participants>
                <participants group_id="P7" count="19">Not everyone accepted protocol amendment allowing to enter extension period or was asked to enter.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="36"/>
                <participants group_id="P7" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Higher Dose</title>
          <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
        </group>
        <group group_id="B2">
          <title>Lower Dose</title>
          <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
        </group>
        <group group_id="B3">
          <title>40 mg Fixed Dose</title>
          <description>40 mg AZD1656 add on to metformin, fixed dose</description>
        </group>
        <group group_id="B4">
          <title>20 mg Fixed Dose</title>
          <description>20 mg AZD1656 add on to metformin, fixed dose</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo add on to metformin</description>
        </group>
        <group group_id="B6">
          <title>Glipizide</title>
          <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
        </group>
        <group group_id="B7">
          <title>Open Label</title>
          <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="91"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="88"/>
            <count group_id="B6" value="94"/>
            <count group_id="B7" value="72"/>
            <count group_id="B8" value="530"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.1" lower_limit="34" upper_limit="81"/>
                    <measurement group_id="B2" value="57.1" lower_limit="32" upper_limit="80"/>
                    <measurement group_id="B3" value="54.4" lower_limit="23" upper_limit="77"/>
                    <measurement group_id="B4" value="57.4" lower_limit="35" upper_limit="80"/>
                    <measurement group_id="B5" value="56.9" lower_limit="30" upper_limit="75"/>
                    <measurement group_id="B6" value="57.1" lower_limit="36" upper_limit="78"/>
                    <measurement group_id="B7" value="53.1" lower_limit="20" upper_limit="69"/>
                    <measurement group_id="B8" value="56" lower_limit="20" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="37"/>
                    <measurement group_id="B8" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c: Change From Baseline to 4 Month</title>
        <description>AZD1656 is analyzed in a ANCOVA model (Glipized and Open Label is Not Included in the model), FAS Prior to Rescue</description>
        <time_frame>Baseline to 4th Month</time_frame>
        <population>The population is FAS prior to rescue, using the LOCF values (see table 27 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c: Change From Baseline to 4 Month</title>
          <description>AZD1656 is analyzed in a ANCOVA model (Glipized and Open Label is Not Included in the model), FAS Prior to Rescue</description>
          <population>The population is FAS prior to rescue, using the LOCF values (see table 27 in CSR)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="-1.14" lower_limit="-1.49" upper_limit="-1.01"/>
                    <measurement group_id="O2" value="-1.26" spread="-1.14" lower_limit="-1.49" upper_limit="-1.02"/>
                    <measurement group_id="O3" value="-0.67" spread="-0.62" lower_limit="-0.99" upper_limit="-0.36"/>
                    <measurement group_id="O4" value="-0.61" spread="-0.60" lower_limit="-0.98" upper_limit="-0.24"/>
                    <measurement group_id="O5" value="-0.45" lower_limit="-0.69" upper_limit="-0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG: to Evaluate Change From Baseline to 4 Month, Compared With Placebo, FAS Prior to Rescue.</title>
        <description>AZD1656 is analyzed in a ANCOVA model (Glipized and Open Label is Not Included in the model), FAS Prior to Rescue.</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is FAS prior to rescue, using the LOCF values (see table 29 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
        </group_list>
        <measure>
          <title>FPG: to Evaluate Change From Baseline to 4 Month, Compared With Placebo, FAS Prior to Rescue.</title>
          <description>AZD1656 is analyzed in a ANCOVA model (Glipized and Open Label is Not Included in the model), FAS Prior to Rescue.</description>
          <population>The population is FAS prior to rescue, using the LOCF values (see table 29 in CSR)</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.818" spread="-1.373" lower_limit="-1.331" upper_limit="-0.304"/>
                    <measurement group_id="O2" value="-1.08" spread="-1.642" lower_limit="-1.603" upper_limit="-0.558"/>
                    <measurement group_id="O3" value="0.041" spread="-0.652" lower_limit="-0.656" upper_limit="0.738"/>
                    <measurement group_id="O4" value="0.024" spread="-0.737" lower_limit="-0.757" upper_limit="0.804"/>
                    <measurement group_id="O5" value="-0.182" lower_limit="-0.71" upper_limit="0.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SMPG: Change From Baseline to 4 Month, Compared With Placebo, FAS Prior to Rescue.</title>
        <description>AZD1656 is analyzed in a ANCOVA model (Glipized and Open Label is Not Included in the model), FAS Prior to Rescue.</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is FAS prior to rescue, using the LOCF values (see table 31 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
        </group_list>
        <measure>
          <title>SMPG: Change From Baseline to 4 Month, Compared With Placebo, FAS Prior to Rescue.</title>
          <description>AZD1656 is analyzed in a ANCOVA model (Glipized and Open Label is Not Included in the model), FAS Prior to Rescue.</description>
          <population>The population is FAS prior to rescue, using the LOCF values (see table 31 in CSR)</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.596" spread="-2.206" lower_limit="-2.176" upper_limit="-1.016"/>
                    <measurement group_id="O2" value="-1.557" spread="-2.155" lower_limit="-2.117" upper_limit="-0.997"/>
                    <measurement group_id="O3" value="-0.874" spread="-1.586" lower_limit="-1.591" upper_limit="-0.157"/>
                    <measurement group_id="O4" value="-0.604" spread="-1.437" lower_limit="-1.472" upper_limit="0.265"/>
                    <measurement group_id="O5" value="-0.213" lower_limit="-0.799" upper_limit="0.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OGTT/Plasma Glucose</title>
        <description>The relative change in AUC</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is FAS prior to rescue, using the LOCF values (see table 142 in CSR)The first 50% of patients enrolled in the study were supposed to undertake OGTT, actual number participating was 52%. However, more than 60% of the OGTT patients were excluded from the analyses, as their measurements did not comply with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
        </group_list>
        <measure>
          <title>OGTT/Plasma Glucose</title>
          <description>The relative change in AUC</description>
          <population>The population is FAS prior to rescue, using the LOCF values (see table 142 in CSR)The first 50% of patients enrolled in the study were supposed to undertake OGTT, actual number participating was 52%. However, more than 60% of the OGTT patients were excluded from the analyses, as their measurements did not comply with the protocol</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.82" upper_limit="1.02"/>
                    <measurement group_id="O2" value="0.84" lower_limit="0.75" upper_limit="0.96"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.86" upper_limit="1.22"/>
                    <measurement group_id="O4" value="0.99" lower_limit="0.84" upper_limit="1.16"/>
                    <measurement group_id="O5" value="0.99" lower_limit="0.88" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OGTT/Insulin</title>
        <description>The Relative Change in AUC FAS Prior to Rescue</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is FAS prior to rescue, using the LOCF values (see table 146 in CSR)The first 50% of patients enrolled in the study were supposed to undertake OGTT, actual number participating was 52%. However, more than 60% of the OGTT patients were excluded from the analyses, as their measurements did not comply with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
        </group_list>
        <measure>
          <title>OGTT/Insulin</title>
          <description>The Relative Change in AUC FAS Prior to Rescue</description>
          <population>The population is FAS prior to rescue, using the LOCF values (see table 146 in CSR)The first 50% of patients enrolled in the study were supposed to undertake OGTT, actual number participating was 52%. However, more than 60% of the OGTT patients were excluded from the analyses, as their measurements did not comply with the protocol</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.66" upper_limit="0.99"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.85" upper_limit="1.36"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.69" upper_limit="1.35"/>
                    <measurement group_id="O4" value="0.90" lower_limit="0.69" upper_limit="1.16"/>
                    <measurement group_id="O5" value="0.91" lower_limit="0.74" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OGTT/C-peptide</title>
        <description>The relative change, FAS prior to rescue</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is FAS prior to rescue, using the LOCF values (see table 150 in CSR)The first 50% of patients enrolled in the study were supposed to undertake OGTT, actual number participating was 52%. However, more than 60% of the OGTT patients were excluded from the analyses, as their measurements did not comply with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
        </group_list>
        <measure>
          <title>OGTT/C-peptide</title>
          <description>The relative change, FAS prior to rescue</description>
          <population>The population is FAS prior to rescue, using the LOCF values (see table 150 in CSR)The first 50% of patients enrolled in the study were supposed to undertake OGTT, actual number participating was 52%. However, more than 60% of the OGTT patients were excluded from the analyses, as their measurements did not comply with the protocol</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.85" upper_limit="1.10"/>
                    <measurement group_id="O2" value="1.11" lower_limit="0.96" upper_limit="1.29"/>
                    <measurement group_id="O3" value="0.90" lower_limit="0.74" upper_limit="1.10"/>
                    <measurement group_id="O4" value="0.95" lower_limit="0.81" upper_limit="1.13"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.87" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OGTT/Pro-insulin/Insulin</title>
        <description>The relative change, FAS prior to rescue</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is FAS prior to rescue, using the LOCF values (see table 154 in CSR)The first 50% of patients enrolled in the study were supposed to undertake OGTT, actual number participating was 52%. However, more than 60% of the OGTT patients were excluded from the analyses, as their measurements did not comply with the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
        </group_list>
        <measure>
          <title>OGTT/Pro-insulin/Insulin</title>
          <description>The relative change, FAS prior to rescue</description>
          <population>The population is FAS prior to rescue, using the LOCF values (see table 154 in CSR)The first 50% of patients enrolled in the study were supposed to undertake OGTT, actual number participating was 52%. However, more than 60% of the OGTT patients were excluded from the analyses, as their measurements did not comply with the protocol</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.496" lower_limit="1.250" upper_limit="1.791"/>
                    <measurement group_id="O2" value="1.199" lower_limit="0.973" upper_limit="1.476"/>
                    <measurement group_id="O3" value="1.248" lower_limit="0.932" upper_limit="1.672"/>
                    <measurement group_id="O4" value="1.431" lower_limit="1.135" upper_limit="1.805"/>
                    <measurement group_id="O5" value="1.185" lower_limit="0.979" upper_limit="1.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c ≤ 7</title>
        <description>Number of responders ≤ 7, FAS prior to rescue.</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is FAS prior to rescue, using the observed cases (see table 35 in CSR).</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c ≤ 7</title>
          <description>Number of responders ≤ 7, FAS prior to rescue.</description>
          <population>The population is FAS prior to rescue, using the observed cases (see table 35 in CSR).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="78"/>
                <count group_id="O7" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="50"/>
                    <measurement group_id="O7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c ≤ 6.5</title>
        <description>Number of Responders ≤ 6.5, FAS Prior to Rescue</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 228 in CSR).</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c ≤ 6.5</title>
          <description>Number of Responders ≤ 6.5, FAS Prior to Rescue</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 228 in CSR).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="78"/>
                <count group_id="O7" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL-C: Mean Ratio</title>
        <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI.</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 228 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-C: Mean Ratio</title>
          <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI.</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 228 in CSR)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="29.5" lower_limit="1.01" upper_limit="1.13"/>
                    <measurement group_id="O2" value="1.02" spread="20.6" lower_limit="0.97" upper_limit="1.08"/>
                    <measurement group_id="O3" value="1.07" spread="38.5" lower_limit="0.99" upper_limit="1.15"/>
                    <measurement group_id="O4" value="1.04" spread="23.1" lower_limit="0.96" upper_limit="1.13"/>
                    <measurement group_id="O5" value="1.02" spread="19.3" lower_limit="0.97" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL-C: Change From Baseline</title>
        <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI.</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 230 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HDL-C: Change From Baseline</title>
          <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI.</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 230 in CSR)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="6.2" lower_limit="1.02" upper_limit="1.09"/>
                    <measurement group_id="O2" value="1.06" spread="5.1" lower_limit="1.03" upper_limit="1.10"/>
                    <measurement group_id="O3" value="1.05" spread="7.8" lower_limit="1.01" upper_limit="1.09"/>
                    <measurement group_id="O4" value="1.03" spread="4.1" lower_limit="0.99" upper_limit="1.08"/>
                    <measurement group_id="O5" value="1.03" spread="5.3" lower_limit="1.00" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol: Change From Baseline</title>
        <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI.</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 232 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol: Change From Baseline</title>
          <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI.</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 232 in CSR)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="36.9" lower_limit="1.04" upper_limit="1.13"/>
                    <measurement group_id="O2" value="1.08" spread="60.2" lower_limit="1.04" upper_limit="1.12"/>
                    <measurement group_id="O3" value="1.07" spread="41.6" lower_limit="1.02" upper_limit="1.13"/>
                    <measurement group_id="O4" value="1.04" spread="25.3" lower_limit="0.98" upper_limit="1.10"/>
                    <measurement group_id="O5" value="1.03" spread="26.0" lower_limit="0.99" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides: Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 226 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides: Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 226 in CSR)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="82"/>
                <count group_id="O7" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="115.3" lower_limit="39.2" upper_limit="114.4"/>
                    <measurement group_id="O2" value="38.7" spread="99.3" lower_limit="38.7" upper_limit="99.3"/>
                    <measurement group_id="O3" value="19.8" spread="185.3" lower_limit="19.8" upper_limit="185.3"/>
                    <measurement group_id="O4" value="4.4" spread="49.3" lower_limit="4.4" upper_limit="49.3"/>
                    <measurement group_id="O5" value="13.7" spread="139.4" lower_limit="13.4" upper_limit="139.4"/>
                    <measurement group_id="O6" value="18.7" spread="152.8" lower_limit="13.7" upper_limit="139.4"/>
                    <measurement group_id="O7" value="29.8" spread="174.3" lower_limit="18.7" upper_limit="152.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-reactive Protein: Change From Baseline</title>
        <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 234 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein: Change From Baseline</title>
          <description>Geometric mean ratio (safety analysis set, regardless of rescue) and a 95 % CI</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 234 in CSR)</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.88" lower_limit="0.08" upper_limit="0.52"/>
                    <measurement group_id="O2" value="0.08" spread="0.86" lower_limit="-0.14" upper_limit="0.30"/>
                    <measurement group_id="O3" value="0.09" spread="0.99" lower_limit="-0.20" upper_limit="0.30"/>
                    <measurement group_id="O4" value="0.06" spread="0.74" lower_limit="-0.40" upper_limit="0.27"/>
                    <measurement group_id="O5" value="-0.02" spread="0.75" lower_limit="-0.24" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure, Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 237 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure, Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 237 in CSR)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="79"/>
                <count group_id="O7" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="12.6"/>
                    <measurement group_id="O2" value="0.4" spread="9.9"/>
                    <measurement group_id="O3" value="5.7" spread="11.3"/>
                    <measurement group_id="O4" value="0.1" spread="12.6"/>
                    <measurement group_id="O5" value="-0.2" spread="13.7"/>
                    <measurement group_id="O6" value="-1.1" spread="13.5"/>
                    <measurement group_id="O7" value="-0.3" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure, Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 240 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure, Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 240 in CSR)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="79"/>
                <count group_id="O7" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="8.6"/>
                    <measurement group_id="O2" value="1.4" spread="8.5"/>
                    <measurement group_id="O3" value="1.3" spread="9.1"/>
                    <measurement group_id="O4" value="-0.9" spread="10.8"/>
                    <measurement group_id="O5" value="-0.3" spread="8.5"/>
                    <measurement group_id="O6" value="-0.1" spread="7.2"/>
                    <measurement group_id="O7" value="0.5" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse, Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 236 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse, Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 236 in CSR)</population>
          <units>Beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="79"/>
                <count group_id="O7" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="8.8"/>
                    <measurement group_id="O2" value="1.6" spread="7.9"/>
                    <measurement group_id="O3" value="1.3" spread="7.9"/>
                    <measurement group_id="O4" value="0.3" spread="9.1"/>
                    <measurement group_id="O5" value="-1.1" spread="9.4"/>
                    <measurement group_id="O6" value="-0.4" spread="11.6"/>
                    <measurement group_id="O7" value="1.3" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight, Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 244 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Weight, Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 244 in CSR)</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="79"/>
                <count group_id="O7" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.5"/>
                    <measurement group_id="O2" value="-0.6" spread="2.9"/>
                    <measurement group_id="O3" value="-1.2" spread="2.7"/>
                    <measurement group_id="O4" value="-1.4" spread="2.3"/>
                    <measurement group_id="O5" value="-1.0" spread="2.5"/>
                    <measurement group_id="O6" value="1.0" spread="3.4"/>
                    <measurement group_id="O7" value="-0.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcF; Electorcardiagram Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 258 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF; Electorcardiagram Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 258 in CSR)</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="77"/>
                <count group_id="O6" value="83"/>
                <count group_id="O7" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="15.6"/>
                    <measurement group_id="O2" value="4.0" spread="14.5"/>
                    <measurement group_id="O3" value="-2.6" spread="12.6"/>
                    <measurement group_id="O4" value="3.8" spread="17.9"/>
                    <measurement group_id="O5" value="2.2" spread="13.8"/>
                    <measurement group_id="O6" value="2.7" spread="21.5"/>
                    <measurement group_id="O7" value="1.6" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haemoglobin; Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>population is safety analysis set regardless of rescue, using the observed cases (see table 197 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Haemoglobin; Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>population is safety analysis set regardless of rescue, using the observed cases (see table 197 in CSR)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="83"/>
                <count group_id="O7" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.68"/>
                    <measurement group_id="O2" value="-0.18" spread="0.62"/>
                    <measurement group_id="O3" value="0.00" spread="0.63"/>
                    <measurement group_id="O4" value="-0.11" spread="0.69"/>
                    <measurement group_id="O5" value="-0.20" spread="0.71"/>
                    <measurement group_id="O6" value="0.02" spread="0.69"/>
                    <measurement group_id="O7" value="-0.25" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leukocytes; Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 198 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Leukocytes; Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 198 in CSR)</population>
          <units>*10^3 cells/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="83"/>
                <count group_id="O7" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="1.29"/>
                    <measurement group_id="O2" value="0.34" spread="1.59"/>
                    <measurement group_id="O3" value="0.35" spread="1.41"/>
                    <measurement group_id="O4" value="-0.15" spread="1.09"/>
                    <measurement group_id="O5" value="-0.8" spread="1.09"/>
                    <measurement group_id="O6" value="0.27" spread="1.43"/>
                    <measurement group_id="O7" value="-40" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sodium; Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 215 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Sodium; Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 215 in CSR)</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="83"/>
                <count group_id="O7" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.4"/>
                    <measurement group_id="O2" value="-0.7" spread="2.4"/>
                    <measurement group_id="O3" value="-0.4" spread="3.0"/>
                    <measurement group_id="O4" value="-0.1" spread="2.6"/>
                    <measurement group_id="O5" value="0.0" spread="2.6"/>
                    <measurement group_id="O6" value="-0.6" spread="3.3"/>
                    <measurement group_id="O7" value="0.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potassium; Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 214 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Potassium; Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 214 in CSR)</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="82"/>
                <count group_id="O7" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.45"/>
                    <measurement group_id="O2" value="-0.02" spread="0.26"/>
                    <measurement group_id="O3" value="0.00" spread="0.35"/>
                    <measurement group_id="O4" value="-0.01" spread="0.29"/>
                    <measurement group_id="O5" value="-0.02" spread="0.34"/>
                    <measurement group_id="O6" value="0.07" spread="0.39"/>
                    <measurement group_id="O7" value="0.05" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine; Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 211 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine; Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 211 in CSR)</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="82"/>
                <count group_id="O7" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="70.5"/>
                    <measurement group_id="O2" value="-9.9" spread="87.8"/>
                    <measurement group_id="O3" value="8.5" spread="88.7"/>
                    <measurement group_id="O4" value="-8.3" spread="39.1"/>
                    <measurement group_id="O5" value="-0.1" spread="32.2"/>
                    <measurement group_id="O6" value="15.9" spread="67.1"/>
                    <measurement group_id="O7" value="-7.3" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT; Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 206 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>ALT; Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 206 in CSR)</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="82"/>
                <count group_id="O7" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="12.0"/>
                    <measurement group_id="O2" value="1.7" spread="14.8"/>
                    <measurement group_id="O3" value="3.2" spread="17.7"/>
                    <measurement group_id="O4" value="-1.8" spread="-1.8"/>
                    <measurement group_id="O5" value="-0.4" spread="11.3"/>
                    <measurement group_id="O6" value="2.0" spread="15.3"/>
                    <measurement group_id="O7" value="-0.4" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST; Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 207 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>AST; Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 207 in CSR)</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="82"/>
                <count group_id="O7" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="9.8"/>
                    <measurement group_id="O2" value="2.0" spread="11.0"/>
                    <measurement group_id="O3" value="2.8" spread="13.1"/>
                    <measurement group_id="O4" value="-0.6" spread="8.9"/>
                    <measurement group_id="O5" value="-0.1" spread="7.9"/>
                    <measurement group_id="O6" value="2.1" spread="13.3"/>
                    <measurement group_id="O7" value="2.7" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alkaline Phosphatase; Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 208 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Alkaline Phosphatase; Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 208 in CSR)</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="83"/>
                <count group_id="O7" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="17.5"/>
                    <measurement group_id="O2" value="-1.3" spread="13.3"/>
                    <measurement group_id="O3" value="0.0" spread="13.6"/>
                    <measurement group_id="O4" value="-1.8" spread="11.9"/>
                    <measurement group_id="O5" value="-3.4" spread="11.5"/>
                    <measurement group_id="O6" value="-4.2" spread="16.7"/>
                    <measurement group_id="O7" value="-11.7" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin; Change From Baseline</title>
        <description>Summary statistic of change from baseline</description>
        <time_frame>baseline to 4 month</time_frame>
        <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 209 in CSR)</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo add on to metformin</description>
          </group>
          <group group_id="O6">
            <title>Glipizide</title>
            <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
          </group>
          <group group_id="O7">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin; Change From Baseline</title>
          <description>Summary statistic of change from baseline</description>
          <population>The population is safety analysis set regardless of rescue, using the observed cases (see table 209 in CSR)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="83"/>
                <count group_id="O7" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.17"/>
                    <measurement group_id="O2" value="-0.06" spread="0.21"/>
                    <measurement group_id="O3" value="0.02" spread="0.13"/>
                    <measurement group_id="O4" value="-0.05" spread="0.20"/>
                    <measurement group_id="O5" value="-0.01" spread="0.20"/>
                    <measurement group_id="O6" value="-0.07" spread="0.20"/>
                    <measurement group_id="O7" value="-11.7" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F to Characterise the PK Properties of AZD1656.</title>
        <description>The value is calculated using an allometric model (of a patient weighting 75 kg). The value is independent treatment given.</description>
        <time_frame>at 4 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F to Characterise the PK Properties of AZD1656.</title>
          <description>The value is calculated using an allometric model (of a patient weighting 75 kg). The value is independent treatment given.</description>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.29" spread="3.7"/>
                    <measurement group_id="O2" value="9.29" spread="3.7"/>
                    <measurement group_id="O3" value="9.29" spread="3.7"/>
                    <measurement group_id="O4" value="9.29" spread="3.7"/>
                    <measurement group_id="O5" value="9.29" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EC50 to Characterise the PD Properties of AZD1656.</title>
        <description>The value is model based. The value is independent treatment given.</description>
        <time_frame>at 4 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose</title>
            <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose</title>
            <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
          <group group_id="O3">
            <title>40 mg Fixed Dose</title>
            <description>40 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O4">
            <title>20 mg Fixed Dose</title>
            <description>20 mg AZD1656 add on to metformin, fixed dose</description>
          </group>
          <group group_id="O5">
            <title>Open Label</title>
            <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
          </group>
        </group_list>
        <measure>
          <title>EC50 to Characterise the PD Properties of AZD1656.</title>
          <description>The value is model based. The value is independent treatment given.</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2" spread="14"/>
                    <measurement group_id="O2" value="60.2" spread="14"/>
                    <measurement group_id="O3" value="60.1" spread="14"/>
                    <measurement group_id="O4" value="60.2" spread="14"/>
                    <measurement group_id="O5" value="60.2" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline - 6 month</time_frame>
      <desc>Safety was collected in 6 month</desc>
      <group_list>
        <group group_id="E1">
          <title>Higher Dose</title>
          <description>20-200 mg AZD1656 add on to metformin, titrated dose</description>
        </group>
        <group group_id="E2">
          <title>Lower Dose</title>
          <description>10-140 mg AZD1656 add on to metformin, titrated dose</description>
        </group>
        <group group_id="E3">
          <title>40 mg Fixed Dose</title>
          <description>40 mg AZD1656 add on to metformin, fixed dose</description>
        </group>
        <group group_id="E4">
          <title>20 mg Fixed Dose</title>
          <description>20 mg AZD1656 add on to metformin, fixed dose</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo add on to metformin</description>
        </group>
        <group group_id="E6">
          <title>Glipizide</title>
          <description>5-20 mg Glipizide add on to metformin, titrated dose</description>
        </group>
        <group group_id="E7">
          <title>Open Label</title>
          <description>Open label, 20-200 mg AZD1656 add on to metformin, titrated dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failur acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>This iformation is based on tables 182 and 183 in the CSR</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>This iformation is based on tables 182 and 183 in the CSR</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>This iformation is based on tables 182 and 183 in the CSR</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>This iformation is based on tables 182 and 183 in the CSR</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <description>This iformation is based on tables 182 and 183 in the CSR</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>This iformation is based on tables 182 and 183 in the CSR</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>This iformation is based on tables 182 and 183 in the CSR</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <description>This iformation is based on tables 182 and 183 in the CSR</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>This iformation is based on tables 182 and 183 in the CSR</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <description>This iformation is based on tables 182 and 183 in the CSR</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

